% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Liu:177206,
      author       = {A. P. Y. Liu and K. S. Smith and R. Kumar and L. Paul and
                      L. Bihannic and T. Lin and K. K. Maass$^*$ and K. W.
                      Pajtler$^*$ and M. Chintagumpala and J. M. Su and E. Bouffet
                      and M. J. Fisher and S. Gururangan and R. Cohn and T.
                      Hassall and J. R. Hansford and P. Klimo and F. A. Boop and
                      C. F. Stewart and J. H. Harreld and T. E. Merchant and R. G.
                      Tatevossian and G. Neale and M. Lear and J. M. Klco and B.
                      A. Orr and D. W. Ellison and R. J. Gilbertson and A.
                      Onar-Thomas and A. Gajjar and G. W. Robinson and P. A.
                      Northcott},
      title        = {{S}erial assessment of measurable residual disease in
                      medulloblastoma liquid biopsies.},
      journal      = {Cancer cell},
      volume       = {39},
      number       = {11},
      issn         = {1535-6108},
      address      = {New York, NY},
      publisher    = {Elsevier},
      reportid     = {DKFZ-2021-02340},
      pages        = {1519-1530.e4},
      year         = {2021},
      note         = {2021 Nov 8;39(11):1519-1530.e4},
      abstract     = {Nearly one-third of children with medulloblastoma, a
                      malignant embryonal tumor of the cerebellum, succumb to
                      their disease. Conventional response monitoring by imaging
                      and cerebrospinal fluid (CSF) cytology remains challenging,
                      and a marker for measurable residual disease (MRD) is
                      lacking. Here, we show the clinical utility of CSF-derived
                      cell-free DNA (cfDNA) as a biomarker of MRD in serial
                      samples collected from children with medulloblastoma (123
                      patients, 476 samples) enrolled on a prospective trial.
                      Using low-coverage whole-genome sequencing, tumor-associated
                      copy-number variations in CSF-derived cfDNA are investigated
                      as an MRD surrogate. MRD is detected at baseline in $85\%$
                      and $54\%$ of patients with metastatic and localized
                      disease, respectively. The number of MRD-positive patients
                      declines with therapy, yet those with persistent MRD have
                      significantly higher risk of progression. Importantly, MRD
                      detection precedes radiographic progression in half who
                      relapse. Our findings advocate for the prospective
                      assessment of CSF-derived liquid biopsies in future trials
                      for medulloblastoma.},
      keywords     = {biomarkers (Other) / cell-free DNA (Other) / cerebrospinal
                      fluid (Other) / childhood cancer (Other) / liquid biopsy
                      (Other) / measurable residual disease (Other) /
                      medulloblastoma (Other) / microscopic residual disease
                      (Other) / minimal residual disease (Other) / relapse disease
                      (Other)},
      cin          = {B062},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:34678152},
      doi          = {10.1016/j.ccell.2021.09.012},
      url          = {https://inrepo02.dkfz.de/record/177206},
}